Found 48 clinical trials
Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF
/emtricitabine to dolutegravir/lamivudine
- 0 views
- 26 Jan, 2021
- 1 location
DORA: The Safety of Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV in South Africa
reproductive potential living with HIV-1 switched from Efavirenz or Dolutegravir-based antiretroviral therapy on metabolic and neuropsychiatric outcomes.
- 0 views
- 26 Jan, 2021
- 2 locations
Dolutegravir and Darunavir Evaluation in Adults Failing Therapy
DEFT is a randomised, open-label study in HIV-1 infected patients failing first-line antiretroviral therapy (ART). The study compares 2 regimens of second-line ART (dolutegravir and darunavir
- 1172 views
- 25 Mar, 2021
- 32 locations
Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals
This study will evaluate the potential drug-drug interactions between dolutegravir (DTG) and steady state rifapentine (RPT) when RPT is given with isoniazid (INH) daily for 4 weeks (1HP) as part
- 0 views
- 23 Jun, 2021
- 6 locations
Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019
Dolutegravir is a potent integrase strand transfer inhibitor. Abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) is a fixed dose combination regimen containing two nucleoside reverse transcriptase
- 188 views
- 27 Jan, 2021
- 15 locations
The Pharmacokinetics Safety and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
The purpose of this study is to examine the pharmacokinetics, safety, and tolerability of abacavir/dolutegravir/lamivudine dispersible and immediate release tablets in HIV-1-infected children
- 30 views
- 24 May, 2021
- 14 locations
A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults
investigate the safety, efficacy and dose-response of GSK3640254 compared to dolutegravir (DTG), each given in combination with 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) (abacavir/lamivudine [ABC
- 0 views
- 23 Jun, 2021
- 48 locations
Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals
The investigators want to know if ultra-short, effective treatment for latent tuberculosis (TB) infection (LTBI) could dramatically reduce the global incidence of active TB or not. The investigators hypothesize that short-course (4-week) daily isoniazid/rifapentine (INH/RPT) (1HP) is not inferior to standard -course (12 weeks) INH/RPT weekly regimen (3HP) for the …
- 0 views
- 25 Jan, 2021
- 16 locations
Contribution of Dolutegravir to Obesity and Cardiovascular Disease
The goal of the study is to combine a collaborative and translational approach to evaluate the effect antiretroviral regimen switch to a dolutegravir containing regimen compared to continued
- 0 views
- 02 Feb, 2021
- 1 location
Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen
severity of neuropsychiatric symptoms than dolutegravir.
- 0 views
- 23 Jan, 2021
- 1 location